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Biologic and physical characteristics of the non-peptidic, non-digitalis-
like natriuretic hormone. At least three independent groups of natri-
uretic hormones have been isolated over the past ten years. Two, atrial
natriuretic factor (ANF) and brain natriuretic peptide (BNP), are
proteins and the third is made up of digitalis-like substances (DLS). The
present report concerns the isolation, substantial purification and
biologic actions of an entirely different natriuretic hormone (NH) which
appears to be steroidal in nature and an isomer of cortisone. The source
of NH was uremic urine. Purification involved successive chromato-
graphic steps including gel filtration and multiple HPLC runs through
C-18 resins. A translucent crystal ultimately was obtained. The product
was examined using mass spectroscopy with trimethylsilyl derivatiza-
tion. Only one compound was identifiable. The characteristics of the
molecule include: a molecular weight, 360.4; a molecular formula,
C21H28O5; a steroidal nucleus; UV absorption at 220 and 290 nm; and
intrinsic fluorescence. The onset of action occurs within minutes both in
the rat and, as previously shown, in several in vitro systems including
the frog skin, toad bladder, fibroblasts and renal tubular epithelial cells
grown in culture and isolated perfused cortical collecting tubules. In
contrast to DLS, NH has been previously shown not to cross react with
digoxin antibodies. Moreover, when given to intact rats, it produces a
profound natriuresis but little or no kaliuresis. In contrast to ANF and
BNP the compound is active orally as well as intravenously. It is clearly
different from cortisone, based both on its biologic and mass spectro-
scopic characteristics.
It has been known for decades that sodium is largely confined
to the extracellular fluid (ECF) and the total mass of sodium in
the ECF plays a critical role in determining the volume of the
ECF. Characteristically, new sodium enters the body as a
dietary constituent at a rate that is random, both during the
course of a given day and during consecutive 24 hour periods.
Normally, the exclusive route of elimination of sodium from the
body is in the urine.
The nature of the system controlling sodium excretion by the
kidneys has been investigated for many years [1, 2]. As a result,
a large body of knowledge has been accumulated. It has been
well-established that there are elements of the volume control
system that effect sodium excretion other than glomerular
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filtration rate (GFR), the renin-angiotensin-aldosterone system
and renal nerves. In particular, there is a strong likelihood that
one or more natriuretic hormones may regulate sodium excre-
tion and thus ECF volume. At least three groups of natriuretic
hormones have been isolated in recent years. Two, atrial
natriuretic factor (ANF) [3—5] and brain natriuretic peptide
(BNP) [6], are proteins. A third group consists of digitalis-like
substances (DLS) [7, 8]. However, none of the foregoing
substances appears to fulfill the criteria of an endogenous
modulator of sodium excretion that preserves short- and long-
term sodium homeostasis.
In a series of studies from our laboratory, we have reported
on a natriuretic factor obtained from the serum and urine of
uremic patients [9, 10]. This substance has a potent natriuretic
effect but produces minimal kaliuresis in the rat [11]; it inhibits
transepithelial sodium transport by the isolated frog skin [12]
and urinary bladder of the toad [13]; it inhibits sodium efflux by
isolated cell monolayers [11]; and it inhibits sodium reabsorp-
tion by the isolated perfused segment of cortical collecting
tubules of the rabbit [14]. The inhibitory factor has been shown
to be of low molecular weight (< 1000 Daltons) [12], water
soluble, soluble in only a few lipids of high dielectric constant
and to be resistant to heat, and prolonged storage at —80°C and
room temperature [11]. Finally, this substance does not cross
react with digoxin antibodies [15].
In the present studies, we report the substantial purification
of NH to crystalline form and describe additional biologic
properties as well as its molecular weight, formula and partial
structure. NH differs from ANF, BNP and DLS. As with less
purified fractions, it is natriuretic with little or no effect on
potassium excretion. It is active orally as well as intravenously
in the rat and the natriuresis begins within minutes of its
administration. The magnitude of the natriuresis is significantly
related to the dose given and the duration of the natriuresis is
approximately 60 to 90 minutes. The molecular weight of the
molecule is 360.4 Daltons. Its chemical formula is C21H2805. It
is isomeric to cortisone and aldosterone but has fundamentally
different properties from both. NH may be a key element of the
sodium or volume control system in vivo. Finally, because it is
naturally occurring, produces natriuresis without correspond-
ing kaliuresis, is active orally as well as intravenously and is
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extremely stable, we believe this molecule could have impor-
tant therapeutic applications.
Methods
In previous publications we have described the initial steps in
the isolation and purification of NH [9—13]. In brief, individual
or consecutive 24-hour urine collections were obtained from
chronically uremic patients (creatinine clearance less than 25
mi/mm), most of whom had chronic interstitial renal disease and
none of whom was nephrotic. All patients were on an unre-
stricted sodium diet, and none was on maintenance hemodial-
ysis. The volume, sodium and creatinine concentrations of each
24-hour urine collection were measured and the samples were
lyophilized (Virtis Freeze Mobile II Gardiner, New York, USA)
to approximately 20 ml of sludge. The latter was redissolved in
demineralized water to a total volume of 100 ml and divided into
four aliquots of 25 ml, each equivalent to six hours of original
urine. The contents of each aliquot were centrifuged for 10
minutes at 4°C and the supernatant filtered through Whatmann
#1 ifiter paper. The 25 ml aliquots of the concentrated urine
samples were applied to individual 2.5 x 95 cm columns packed
with Sephadex G-25 medium grade (Pharmacia Fine Chemicals,
Inc., Piscataway, New Jersey, USA). Elution was carried out at
4°C by gravity at a rate of 55 to 65 mI/hr with a solution of 10 m'i
ammonium acetate at pH 6.8. The effluent solution was col-
lected in 100, 18 x 150 mm glass tubes (12 ml) using an
automated fraction collector (model 7000 Ultrorac, LKB Pro-
ducter AB, Stockholm, Sweden). The ultraviolet absorption at
280 nm (LKB Uvicord) and the electrical conductivity (model
5300B Conductolyzer with 53 12B Conductivity cell, LKB Pro-
ducter AB) were traced on-line.
Biologic activity was confined to approximately 7 to 10 tubes
immediately following the tubes containing sodium, potassium,
urea and creatinine in high concentration (that is, the "salt
peak"). The contents of all of the positive tubes, as determined
by the cell assay to be described below, were pooled. This
pooled specimen was then lyophilized to dryness in a glass
container, redissolved to 3 ml with demineralized water and
stored at —80°C. Each ml of this solution is equivalent to the
volume of original urine excreted in two hours. The amount of
NH contained in one hour of original urine is defined as one
unit. Two or more units from the relyophilized post-salt peak of
the G-25 eluate were subjected to assay in the rat, using the
bioassay method previously described [9, 10].
In the present studies, additional methods and procedures
were employed. If the rat assay was positive, the biologically
active fractions of the post-salt peak of the 0-25 eluate were
applied to a reverse phase chromatography column, RP-C-18
(Altex Scientific, Berkeley, California, now Beckman Instru-
ments, Brea, California, USA), and eluted with a gradient of 0.2
M pyridinium acetate/methanol (pH 5.5) in which the methanol
concentration was varied in a stepwise manner from 20 to 70%.
The eluate samples were collected in an automated fraction
collector containing either 50 or 100 tubes. Individual tubes
were evaporated to dryness employing a "Speed Vacuum"
(Savant Instruments, Farmingday, New York, USA), redis-
solved in demineralized water, then tested for biological activ-
ity using the MDBK cell bioassay (see below).
The contents of all positive tubes from the six hour aliquots
from one or more 24-hour urine collections were combined and
relyophilized. Two units of each such pooi were dissolved in 1
ml of synthetic ultrafiltrate of plasma and bioassayed in the rat.
If positive, the remainder of the pool was rechromatographed
using the same RP-C-18 column and an isocratic pyridinium
acetate/methanol (44 2%) buffer (pH 5.5). The cell assay and
rat assay sequence just described was repeated and another
HPLC run, using only the positive tubes from the previous run,
was performed using the above isocratic buffer (at least two
HPLC runs using isocratic buffer were performed). At the end
of this sequence, all activity was found in one to three consec-
utive tubes of eluate, which, when combined and lyophilized,
contained a clear crystalline material. This material was then
subjected to various physiologic and biochemical studies, in-
cluding mass spectroscopy.
Coded samples of redissolved biologically active material and
comparably treated inactive material were investigated by mass
spectroscopy. Aliquots of each set of samples were reacted
with a large excess of 1: 1 pyridine:BSTFA (bistrimethylsilyl
trifluoroacetamide) at 50°C for 30 minutes. The resulting mix-
ture was then applied to a high resolution E-I (electron impact)
mass spectrometer.
Intrinsic fluorescence and fluorescamine dependent fluores-
cence were measured on the HPLC eluates using an Aminco
fluorometer (American Instrument Co., Silver Springs, Mary-
land, USA) or a Beckman fluorometer (Beckman Instruments).
Sodium activity of the original 24 hour urines, the 0-25 eluates
and the test solutions given to rats for bioassay purposes, were
measured using an E4 Electrolyte Analyzer (Beckman). Radio-
activity was counted using a scintillation counter (Beckman LS
3-801) with a Ready Safe scintillation cocktail.
The microassay used to measure NH activity in 0-25 and
HPLC eluate fractions measures the degree of inhibition of the
uptake of 86Rb by MDBK (Malbin-Darby bovine kidney) cell
cultures. The cells are grown for four days at 37°C in Dulbec-
Co's modified Eagle medium (DMEM, Gibco #430-2100) con-
taining fetal calf serum and antimicrobial agents in an atmo-
sphere of 5% C02, 95% air.
From 0.04 to 0.08 units of test solution were added to
individual 2 mm2 wells containing approximately 200,000
MDBK cells grown in monolayer to confluency. After preincu-
bation, 5 x i05 cpm of 86Rb and an additional 0.04 to 0.08 units
of test material were added to each well. Fifteen minutes later
the reaction was stopped with 0.5 ml of cold PBS and each well
was washed twice with 0.5 ml of cold PBS. TCA (0.5 ml of 5%)
was added to each well and incubated for 10 minutes at 37°C to
release the radioactivity from the cells. The supernatant solu-
tions were transferred to one ml microfuge tubes and 86Rb
activity was counted in duplicate on 100 l aliquots. The cells
were then washed with PBS, digested in HNO3, oven dried for
12 hours, and the total protein determined [16]. The results
were expressed as counts of 86Rb/ng protein. The ratio of 86Rb
to protein is a measure of the uptake of rubidium into the ICF
per unit of cell protein. The experimental values were compared
to control samples incubated simultaneously under the same
conditions. The degree of inhibition was expressed as the
percent reduction in 86Rb uptake by the MDBK cells.
In Figure 1, the effect of a G-25 fraction of uremic urine on
the degree of inhibition of 86Rb uptake by MDBK cells is shown
and is compared with the effect of the same material on sodium
excretion in the rat bioassay. The results of a twofold increase
Bricker et a!: Natriuretic hormone 939
2U 4U 0.05U O.1U
Fig. 1. Comparison of the rat bioassay with the MDBK cell bioassay
for NH activity using G-25 eluate. The relationship between dose and
response is shown with both assays. In the rat bioassay the doses of NH
were forty times greater than in the cell assay. The cells were grown at
37°C in Dulbecco's modified Eagle medium (Gibco #430-2100). The
cells became confluent in four days at a concentratrion of approxi-
mately 106 cells per well.
in the dosage of the test material are shown for both assays. At
both dosages, 40 times more NH was used in the rat assay than
in the microassay. Both assays were positive with both doses of
test material and the effects were approximately twice as great
with the larger dose in each assay.
The suppression of 86Rb uptake by MDBK cells can be seen
with any substance that inhibits Na-K-ATPase and is not
specific for NH. The MDBK cell assay did make it possible to
isolate a Na-K-ATPase active substance to a small number of
tubes rather than requiring a rat assay to be done on every tube
removed from the column.
The rats used for the biological assay were female Sprague-
Dawley rats weighing between 200 and 225 g. All rats were
maintained on demineralized water and on a synthetic sodium-
free diet and were fed 3 m of sodium chloride by orogastric
tube each 24 hours. Thirty-six hours before the assay was
performed, 20 mrt NaCI was substituted for the demineralized
drinking water. A positive assay is defined as an increase of
greater than I Eq/min in the average rate of sodium excretion
during the experimental phase (6 consecutive 10-minute urine
collection periods following NH administration) compared to
the average rate of sodium excretion during a 40- minute control
phase.
Rat bioassays were also performed after the administration of
NH given by orogastric tube rather than by i.v. administration.
All the conditions of the rat bioassays were identical to those
used in the standard i.v. protocol, except that the test substance
was dissolved in two ml of demineralized water and adminis-
tered orally over a 10 minute period.
Rat assays were also performed using several other test
substances given intravenously to compare the results obtained
with NH. These include ouabain and digoxin both of which
were infused at a constant rate throughout the experimental
phase and ANF and BNP which were given both as a 10 minute
infusion and throughout the experimental phase.
All subjects whose urine was utilized in this study had given
informed consent for the use of their urine in the isolation of
NH. The protocol was approved by an institutional review
board.
Results
NH activity from G-25 eluate
The results of NH bioassays in the rat from the post-salt
30 2 fraction of G-25 eluates of uremic patients have been described
previously [9, 101. A current representative experiment is
20 presented in Figure 2, in which eluate from six hours of uremic
urine (6 units) was used. Values are shown for sodium and
10 potassium excretion rates during a 40-minute control period and
during six ten-minute experimental periods. The mean values
0 for sodium excretion (UNaV) in Eq/min increased from 2.0
during the control phase to 4.65 during the experimental phase.
The peak value was 5.8 Eq/min. In contrast to sodium
excretion, there was no change in potassium excretion during
the experimental phase.
Results from the pyridinium acetate methanol gradient and
initial isocratic HPLC runs
The remainder of the data relate to progressive stages of
purification of NH using high performance liquid chromatogra-
phy with a pyridinium acetate methanol buffer system. Table 1
shows the results obtained from 23 bioassays of NH subjected
to one or more HPLC runs. Each experiment was performed on
an individual rat. Values for GFR averaged 0.55 ml/min in the
control phase and 0.62 mllmin during the experimental phase.
The increase of 0.08 0.07 mi/mm was not statistically signif-
icant. Sodium excretion rate following the infusion of NH
increased from the control level in all 23 experiments. The
increments ranged from 1.18 to 8.63 Eq/min (mean value, 3.36
1.83 p.Eq/min). Potassium excretion (Table 1) increased in 19
rats; however, in only one rat did the increase exceed 1.0
Eq/min, and the mean change for the group was 0.48 0.32
pEq/min. The ratio of UNaV/UKV for the group was 7.0.
From the data in Table 1, it is not possible to evaluate the
dose response relationship between NH and UNaV because the
patients had varying degrees of uremia and the eluates tested
were from amples subjected to either one or more HPLC runs.
Moreover, the samples were from single collections from indi-
vidual patients, pools from multiple collections from individual
patients, or pools obtained from multiple patients. A dose
response curve from a single pool of highly purified NH will be
described subsequently.
Multiple fluorescent and UV peaks were observed in the
on-line tracing of the consecutive tubes of eluate from the
pyridinium acetate methanol gradient and the initial isocratic
HPLC runs. All of the tubes containing biologically active
material in the cell bioassay (see Methods and below) from the
HPLC run using the methanol gradient were pooled and an
aliquot of this pool was determined to be natriuretic in the rat.
One hundred units of the pooled material were rechromato-
graphed using the isocratic buffer. Once again the contents of all
tubes containing biological activity were pooled. Figure 3
depicts the UV spectrum from this pool. Two broad UV
maxima are evident: one is at approximately 220 nm; the other
is at 290 nni. In Table 2, a dose response curve from this pool
is presented (the 5 experiments shown are also included in
Table 1). In each experiment, from 1 to 24 units of test
substance were used. The data show a highly significant rela-
tionship (R2 = 0.96) between the dose of NH and LUNaV. The
values for LUKV are substantially less than those for 1UNaV,
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4.C. Fig. 2. Effects of G-25 eluate on sodium and
potassium excretion in the rat with a solitary
unitsl0 mi/mm. The values for sodium excretion are
remnant kidney. The closed bars represent the
mean values for sodium excretion and the2
open bars potassium excretion before and
after a 10 minute infusion of 6 units of test
material in a uremic rat with a GFR of 0.42
0• expressed as 1UNaV per consecutive 10 mm
interval over the sixty minute period followingControl 10 20 30 40 50 60 70 the infusion of the test fraction (the mean
control value for UNaV is subtracted from theUremic rat (GFR:0.42 mI/mm) experimental values to determine UNaV).
Table 1. Results of the administration of natriuretic hormone from uremic urine after purification by high pressure liquid chromatography in
23 rats
Exp.
#
G
Cont
FR ml/min
Exp. Cont
UNaV isEqimin UkV p.Eq/min
Experimental EAperimental
Cont 20 mm 40 mm 60 mm I20 mm 40 miii 60 mm I z
1. 0.45 0.47 0.02 3.81 4.96 5.04 4.97 4.99 1.18 2.5 2.8 2.73 2,71 2.75 0.25
2. 0.41 0.47 0.06 1.48 7.26 6.43 6.53 6.74 5.65 1.5 2.35 1.90 2.16 2.14 0.64
3. 0.75 0.62 —0.13 1.05 4.99 2.92 1.60 3,17 1.12 1.74 2.0 1.79 1.30 1.70 —0.04
4. 0.59 0.72 0.13 1.73 5.21 6.95 7.67 6.61 4.88 1.68 2.38 2.17 2.20 2.25 0,57
5. 0.45 0.44 —0.01 2.45 5.66 5.21 4.26 5.04 2.59 1.84 1.99 1.93 1.58 1.83 —0.01
6. 0.28 0.34 0.06 1.18 2.31 2.82 3.30 2.81 1.63 2.13 2.52 2.65 2.70 2.62 0.49
7. 0.51 0.60 0.09 0.76 2.09 3.05 4.18 3.12 2.36 2.21 2.85 2.76 2.82 2.81 0.60
8. 0.55 0.61 0.06 3.72 4.35 5.56 5.83 5.25 1.53 2.64 2,49 2.67 2.76 2.64 0.00
9. 0.41 0.48 0.07 2.91 5.82 5.29 5.68 5.60 2.69 1.71 2.25 2.17 2.17 2.20 0.49
10. 0.52 0.63 0.11 2.81 5.49 5.36 4.70 5.18 2.37 2.08 2.79 2.79 2.58 2.72 0.64
11. 0.43 0.49 0.06 3.04 8.02 5.73 6.04 6.60 3.56 2.25 2.16 2.22 2.29 2.22 —0.03
12. 0.71 0.71 0.00 5.75 9.18 10.40 10.28 9.96 4.21 1.94 2.30 2.41 2.52 2.41 0.47
13. 0.39 0,45 0.06 1.29 1.42 2.68 3.36 2.49 1.20 1.45 1.53 1.69 1.86 1.69 0.24
14. 0.82 1.03 0.21 4.24 5.99 6.94 6.73 6.55 2.31 2.60 3.60 2.75 2.85 3.07 0.47
15. 0.62 0.75 0.13 1.47 3.16 3.74 4.68 3.83 2.36 2.30 2.77 2.68 2.75 2.73 0.43
16. 0.79 0.96 0.17 1.18 5.25 6.00 6.12 5.79 4.61 1.64 2.37 2.26 2.50 2.38 0.74
17. 0.62 0.64 0.02 2.24 10.4 7.77 6.94 8.37 6.13 1.90 2.63 2.27 2.06 2.32 0.42
18. 0.55 0.63 0.08 1.61 6.86 6.48 6.91 6.75 5.14 1.50 2.65 2.69 2.65 2.66 1.16
19. 0.58 0.65 0.07 2.37 3.22 4.67 4.97 4.29 1.92 1.80 1.96 2.15 2.21 2.11 0.3!
20. 0.58 0.78 0.20 1.92 4.44 5.07 5.05 4.85 2.93 2.88 3.26 3.66 3.39 3.44 0.56
21. 0.37 0.45 0.08 1.93 5.76 5.36 5.95 5.69 3.76 1.37 2.31 1.97 2.24 2.11 0.80
22. 0.37 0.50 0.13 0.27 0.81 4.38 5.98 3.72 3.45 0.78 1.43 1.91 1.90 1.75 0.97
23. 1.02 1.10 0.08 3.88 14.70 12.20 10.20 12.5 8.63 2.11 3.27 2.70 2.89 2.95 0.84
Average 0.55 0.62 0.08 2.30 5.54 5.65 5.73 5.65 3.36 1.9 2.46 2.39 2.39 2.41 0.48
The GFR, UNaV and UKV values are shown for 23 rats receiving varying doses of varying purity of NH. The average of 3 to 4, 10-minute control
periods is shown for each rat. Three consecutive 20-minute experimental periods (each the average of two 10-mm periods) following the
administration of NH is also shown. In each experiment 5 is the mean of the experimental data in Eq/min. The iUNaV and UKV values represent
the mean of the experimental periods minus the mean of the control periods. Standard deviations are shown for values.
with a ratio of ZUNaV/UKV of 5.35 in four of the five reduced to three, two intrinsic and one fluorescamine dependent
experiments. In the fifth experiment UKV was 0. (Fig. 4). The first peak was fluorescamine- dependent correspond-
ing to tubes numbered 43 to 50. The second and third peaks
Results from subsequent HPLC runs exhibited intrinsic fluorescence and corresponded to tubes num-
After the second reverse-phase HPLC run using the same C-18 bered 51 to 58 and 59 to 65. A UV scan was performed on the
resin columns and the isocratic pyndinium acetate methanol contents of one tube from all three fluorescent peaks (Fig. 5). Only
buffer, the fluorescent peaks of the consecutive eluate tubes were the tube from the third fluorescent peak exhibited a UV spectrum
Fig. 3. The UV scan of the pooled eluate
from the first isocratic HPLC run. The figure
demonstrates two UV maxima in this
biologically active material. One is at
approximately 220 nm, the other
approximately 290 nm.
Table 2. Dose response from a single pool of rechromatographed
natriuretic hormone in 5 different rats
Experiment #
Dose in
units
GFR
mi/mm
UaV IUKV
pEq/mmn
IXUNaV/
UKV
1. 1 0.45 1.18 0.25 4.72
2. 6 0.41 2.69 0.41 6.56
3. 6 0.55 1.53 0.00 —
4. 12 0.55 5.14 1.16 4.43
5. 24 1.02 8.59 1.51 5.70
The effects of increasing doses of purified NH in the rat bioassay are
shown. Each study was performed on a separate test animal using from
ito 24 units of NH from the same pool of test material. 1UNaV/UKV
is a ratio of the simultaneous values for the increase in the excretion
rates of the two solutes.
similar to that observed with the biologically active pool from the
first isocratic HPLC run shown in Figure 3.
The contents of the tubes of each of the three fluorescent
peaks shown in Figure 4 were pooled into three separate
sub-pools, and 20 units of each sub-pool were bioassayed in the
rat. The results are presented in Table 3. No natriuresis was
produced by the first sub-pool and minimal activity was pro-
duced by the second. Marked activity was observed following
the administration of 20 units of sub-pool 3.
In examining the third fluorescent peak (Fig. 4), a shoulder
was noted on the downslope suggesting non-homogeneity of the
contents of this peak. This was better illustrated in an enlarge-
ment of peaks 2 and 3 shown in Figure 6. Consequently, the
seven tubes in peak 3 were divided into two groups (tubes 59 to
63 and 64 to 65). The bioassay results from these two groups are
shown in Table 4. No natriuretic activity was observed in the
pool of the first five tubes; all of the natriuretic activity was
found in the pool of the last two tubes.
Over 200 units of pooled material from the shoulder of peak
three, from multiple HPLC runs, were lyophilized to dryness.
The material obtained was translucent, white, and crystalline.
These biologically active crystals along with similarly prepared
biologically inactive material were analyzed by mass spectros-
copy (MS). The results are summarized in Table 5. Each set of
material was placed into a series of coded tubes and studied
with and without denvitization with tnmethylsilyl (TMS). Nei-
ther of the two biologically inactive pools disclosed any signif-
icant ionization particles or fragments, as the TMS derivative
by electron impact (El) or by fast atom bombardment (FAB).
The tubes containing the biologically active material demon-
strated an apparent ion (M+) at a molecular weight of 576. The
three TMS derivatives accounted for 216 of the 576 Daltons.
Thus the molecular weight of the single detectable molecule
was 360.4. The empirical formula of the MS positive species
was C21H2805. This species, as noted, was only observed in the
biologically active tubes and was not present in similarly
prepared, non-biologically active samples. An ion at 331-TMS3
(C5H703 TMS3), was present only in the active samples. In
Figure 7, the substructure of the ion (C5H703) presumed to be
the nucleus of NH is shown. Another ion, shown in Table 5,
designated at MIZ 283-TMS2 was also shown but this species
did not maximize with the 576 and 331 ions. A 576 peak was not
present and no 331 mass was detected in the biologically
inactive fractions.
Results of the oral administration of purjfied NH
From 1 to 2 units of the crystalline material, obtained from
the final pool of purified NH (from the shoulder of peak 3) were
given to a series of rats by orogastric tube over a ten minute
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Fig. 4. The tracing offluorescence of substantially purified NH in the
HPLC eluate. A fluorescamine dependent peak, corresponding to tubes
43 to 50, precedes the two natural fluorescent peaks and was biologi-
cally inactive. The natural fluorescent peaks correspond to tubes 51 to
58 and 59 to 65 respectively. The downslope of the last peak exhibits a
shoulder corresponding to tubes 64 to 65.
period in 2 ml of distilled water. A representative experiment is
shown in Figure 8. The onset of natriuresis was slightly delayed
in comparison to the i.v. assay shown in Figure 2. However, a
marked natriuresis was observed which peaked at 40 to 50
minutes.
NH compared to other endogenous natriuretic substances
A series of studies was performed in rats with a single
remnant kidney [17] to compare the effects of ANF, BNP,
ouabain and digoxin to NH. In Figures 9A and 9B, values for
UNaV and UKV are shown before and after ten minute infusions
of ANF and BNP in representative rats. The respective dosages
of the two compounds are shown in the figures. Both of the
natriuretic peptides produced a maximum natriuretic effect
during the period of infusion and the excretion rates fell
2.60
2.40
2.20
2.00
1.80
0
1.400
U)
.0< 1.00
0.80
0.60
0.40
0.20
0.00
Sample Units GFR mi/mm UNaV pEqimin
Peak #1 20 0.40 —0.65
Peak #2 20 0.51 1.01
Peak #3 20 0.37 5.17
continuously thereafter toward control values. There was mm-
80 imal kaliuresis.
In Table 6, detailed data regarding the effects of ANF and
BNP are shown. In these eleven experiments, one or the other
natriuretic peptide was infused throughout the 60-minute exper-
imental period. The results of the six ten-minute experimental
urine collections in each rat were averaged and compared to the
respective mean control value. The data show that both ANF
and BNP produced substantial natriuresis. The kaliuretic re-
sponse to ANF was minimal and to BNP moderate. The ratio of
UNaV/UKV was 16.2 for ANF and 4.47 for BNP.
In Table 7, detailed studies are shown for eight rats receiving
constant infusions of either ouabain or digoxin (the dosages
were 0.5 mg/hr and 1 mg/hr. respectively). The data show
essentially no natriuresis and significant kaliuresis. The mean
ratio of UNaV/IUKV was 0.11. There was no significant
change in GFR from the control to the experimental phases.
Table 8 demonstrates the effects of five different steroids on
GFR, UNaV and UKV in uremic rats, All drugs were given by
constant infusion over 60 minutes in the manner described
above. In none of the experiments did either LUNaV or £UKV
exceed 1.0 Eq/min. These results demonstrate essentially no
natriuresis and comparable kaliuresis when compared with the
effect of NH in the uremic rat (Table 1).
The analyses used in Tables 1, 6, 7 and 8 compare the control
values with the experimental values for GFR, UNaV and UkV.
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Fig. 5. UV scan of tubes 47, 54, and 64 from the fluorescent peaks
shown in Figure 4. The lowest curve is from tube 47; the middle curve
is from tube 54 and the upper curve is from tube 64. Only the upper
curve exhibits UV maxima at approximately 220 to 290 nm and biologic
activity was confined to the upper curve.
Table 3. Results of rat bioassays using 20 units of natriuretic
hormone from each of the three fluorescent peaks shown in Figure 4
and described in the text
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Fig. 6. Fluorescent peaks 2 and 3 enlarged from Figure 4, The tracing
defines the shoulder on the downslope of peak 3.
Table 4. Results of rat bioassays using 20 units of natriuretic
hormone from a pool of the first five tubes of the third fluorescent
peak, versus the last two tubes (that is, the shoulder) of the third
fluorescent peak from Figure 4
Sample Units GFR mi/mm UNaV p.Eq/min
Tubes
59—63 20 0.64 0.98
Tubes
64—65 20 0.37 6.92
The zGFR is the difference between the mean GFR of the four
ten-minute control periods prior to starting the infusion of the
test substance and the six ten-minute experimental periods
following the administration of NH. The values shown for
UNaV and UKV are the difference between the mean of the
four ten-minute control periods and the mean of the three
20-minute experimental periods (the 20-mm experimental peri-
ods shown are the mean of two consecutive 10-mm periods).
Discussion
Volume regulation is essential to life in organisms ranging
from the most primitive bacteria to humans. In bacteria, the
Table 5. Mass spectral data of natriuretic hormone
m/z
Biologically
active fractions Biologically-inactive
fractionsFound Calculated
576-T3
(C2H28O5 TMS3) 576.3116 576.3123 Undetected
331-T3
(C,H703 TMS3) 331.1579 331.1581 Undetected
283-T2 283.0909 Undetected
Results of mass spectral analyses of both biologically active and
biologically inactive samples. The samples were examined by EI-MS,
both underivatized and derivatized with Timethylsily L (TMS) and by
FAB (underivatized). The biologically inactive samples did not disclose
any significant components. The molecular weight of the substance
thought to be NH is 576.3116. The molecular weight without the TMS
(whose molecular weight is 216) is 360.4. The ion 331-T3 maximized
with 576-T3, however, an ion at m/z 283-T2 did not maximize.
Abbreviations are: mlz, mass/charge; TMS, Trimethylsily L.
Molecular wt
Formula
OH 0
360
C21, H8, 05
CH2OH
Fig. 7. The substructure, molecular wt and formula of purified NH
examined by mass spectroscopy. See Table 5 and text for more detail.
process involves the control of the constancy of the intracellu-
lar water which in turn depends largely upon the control of
intracellular potassium mass. In advanced species, the require-
ments for volume regulation also include the control of intra-
cellular fluid, however, continued well-being, if not survival,
depends upon the preservation of the ECF sodium mass and
ECF volume. The mechanisms of control, whether acute or
chronic, must minimize the perturbations caused by the addi-
tion of sodium to body fluids.
The regulation of the sodium content of the ECF is due to
modulation of renal sodium excretion regardless of the amount
of sodium ingested, and in chronic renal disease of the number
of remaining nephrons.
Prior to 1961 it was believed that the renal control of sodium
excretion was dependent solely upon changes in GFR and
aldosterone activity. In 1961 de Wardener et al [18] published
studies indicating at least one additional control factor affected
100
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Sodium Excretion
—________________ ____________ — - - — — Fig. 8. The effects on sodium excretion of
one unit of puried NH given by oro-gastric100 tube over a ten minute period in a rat with a
solitary remnant kidney. The horizontal line
represents the mean control value for UNaV.
the rate of sodium excretion by the kidneys. In the years since
that time, a formidable list of natriuretic factors has been
______________________________________________
accrued [1, 2, 11] and particular attention has been focused on
the role of one or more natriuretic hormones on the ongoing
control of sodium excretion. With the discovery of ANF the
existence of one such hormone was confirmed [51. However,
considerable debate still exists as to whether ANF is the final
modulator of sodium excretion. Another class of natriuretic
peptides, BNP, has also been described recently [6], but the
physiologic significance of these compounds remains to be
determined. Among the non-peptidic substances which have
been studied intensively are the digitalis-like substances (digox-
in and ouabain). One of these, digoxin, has recently been
isolated from human urine [19]. However, neither of these
cardiac glycosides produces natriuresis while both are mark-
edly kaliuretic (Table 7). Indeed, the interest in the DLS
substances has switched from a role in volume regulation to an
effect on blood pressure regulation.
In 1968, we presented evidence for a circulating inhibitor of
sodium transport in cow and dog subjected to acute volume
____________________________________________
expansion [20]. Subsequent studies from our laboratory using
the serum and urine from uremic patients subjected to chroma-
tography through Sephadex G-25 have confirmed the existence
of such an inhibitor [9, 101. The data compared the results of the
infusion of test substance from the post-salt fractions of 14 ________________________________________________
normal subjects (19 rat assays) with those from 17 chronically
uremic patients (28 rat assays). The mean value 1.0 SE for the
normal subjects for UNaV was 0.53 0.31 pEq!min, while the
values for the uremic population were 1.62 0.23 Eq/min.
The P value was <0.01. In the above experiments the eluate
from one hour of uremic urine was used. When larger doses of
eluate were used, the magnitude of the natriuresis was in-
creased (Fig. 2).
In the present studies, this natriuretic factor was substantially
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Fig. 9A. The effects of the infusion of ANF on Na and K excretion in
a representative experiment in a rat with a solitary remnant kidney. See
legend to Figure 2 for description. Additional data are contained in table
6. B. The effects of the infusion of BNP on Na and K excretion in a
representative experiment in a rat with a solitary remnant kidney.
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Table 6. Results of the infusion of atrial natriuretic factor (A) and brain natriuretic peptide (B) on sodium and potassium excretion in
individual rats
UNaV pEqimin UkV pEqimin
GFR mi/mm Experimental Experimental
Exp. Cont Exp. A Cont 20 mm 40 mm 60 mm A Cont 20 mm 40 mm 60 mm A
(A) ANF
1. 0.13 0.34 0.21 0.33 10.4 22.6 15.2 15.7 0,65 2.63 1.95 1.94 1.52
2. 0.45 0.78 0.33 0.69 8.41 9.67 8.59 8.20 3.94 5.04 1.69 1.69 —1.15
3. 0.61 0.75 0.14 1.28 1.71 5.74 14.4 6.0 1.38 1.77 1.94 1.91 0.49
4. 0.28 0.42 0.14 0.84 2.43 9.72 8.98 6.2 0.88 0.97 1.14 1.00 0.16
5. 0.87 1.46 0.59 0.53 4.81 11.6 9.57 8.13 1.24 1.90 2.43 2.33 0.98
6. 0.28 0.67 0.39 0.70 9.91 9.83 7.34 8.33 0.62 1.90 1.76 1.66 1.25
Average 0.43 0.73 0.30 0.73 6.28 11.5 10.7 8.76 1.45 2.37 1.82 1.75 0.54
(B) BNP
1. 0.23 0.56 0.33 0.60 3.91 5.38 4.32 3.94 0.64 1.56 1.34 1.12 0.70
2. 2.03 2.57 0.54 0.35 0.54 9.46 10.10 6.35 0.77 1.89 4.05 3.95 2.53
3. 0.79 0.93 0.14 0.99 3.31 5.67 5.95 3.99 0.98 1,59 1.68 1.61 0.65
4. 1.31 1.40 0.09 0.43 1.38 6.06 3.13 3.09 0.72 1.14 1.89 1.28 0.72
5. 0.34 0.52 0.18 0.76 0.88 5.63 18.0 7.41 0.74 0.84 1.52 2.65 0.93
Average 0.94 1.20 0.26 0.62 2.00 6.44 8.30 4.96 0.77 1.40 2.09 2.12 1.11
1.83
See legend to Table 1.
Table 7. Effect of the infusion of ouabain and digoxin on sodium and potassium excretion in individual rats
Exp. GFR mi/mm UNaV /.LEqlmin UkV pEqimin# Cont Exp. A Cont 20 mm 40 mm 60 mm A Cont 20 mm 40 mm 60 mm A
Ouabain
1. 0.20 0.29 0.09 0.33 0.31 0.53 0.53 0.13 0.32 0.51 1.02 0.92 0.50
2. 0.60 0.65 0.05 0.90 0.84 0.84 0.99 —0.01 0.81 1.40 2.20 2.88 1.35
3. 2.39 2.65 0.26 0.44 1.01 1.04 0.58 0.44 0.93 4.34 9.23 7.93 6.24
4. 2.42 2.53 0.09 0.59 0.68 0.44 0.31 —0.11 0.91 2.70 7.71 8.13 5.27
- -i
Average
Digoxin
5. 0.64 0.62 —0.02 0.35 0.37 0.44 0.38 0.05 0.82 1.29 1.58 1.95 0.79
6. 0.51 0.66 0.15 0.34 0.54 0.84 1.1 0.49 0.71 1.24 1.61 2.03 0.92
7. 1.95 2.11 0.16 0.34 0.39 0.43 0.41 0.07 1.02 1.29 1.64 2.36 0.74
8. 2.13 2.45 0.32 0.28 0.55 1.20 1.30 0.74 1.01 1.01 1.79 1.52 0.43
— —
Average
See legend of Table I.
purified using reverse-phase high performance liquid chroma-
tography. With progressive purification, the activity became
increasingly localized in HPLC eluates and ultimately was
confined to a very limited segment of the eluate. When lyoph-
ilized, the active NH appeared as a white crystalline material.
The UV spectrum of biologically active material exhibited
two maxima, one at approximately 220 nm, the other at
approximately 290 nm (Figs. 3 and 5). A further step used in the
purification and identification process was the measurement of
both intrinsic and fluorescamine dependent fluorescence. One
fluorescamine positive and two intrinsic fluorescent peaks were
observed and have been described in the Results. As also
described, the biological activity was confined to the tubes
corresponding to the descending component of the second of
the two peaks with intrinsic fluorescence. Pools of this "shoul-
der" material were subjected to mass spectroscopy. The obser-
vations suggest that the active species, which we believe to be
the NH, has a steroidal nucleus, a molecular formula of
C21H2805 and a molecular weight of 360.4. The molecule is
isomeric to cortisone, however, differing responses in the
bioassay systems differentiate it from cortisone. Moreover,
although NH and cortisone exhibited major peaks with similar
retention times and mass spectra, the methoxylamine/TMS
derivative of biologically active NH did not indicate the pres-
ence of cortisone by gas chromatography or direct probe. The
molecule also is isomeric to aldosterone, but the effects of NH
are non-genomic [21] and have opposite effects on sodium and
potassium excretion.
Previous studies using isolated anuran membranes in vitro
have shown that NH acts only from the "blood" surface of the
membranes and studies using isolated perfused tubules have
shown that NH acts only from the basolateral surface and not
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Table 8. Effect of the infusion of several steroid hormones on sodium and potassium excretion in individual rats
Exp. Drug/dose
GFR mi/mm
Cont Exp.
UNaV pEqimin UkV jxEq/min
Cont
Experimental
Cont
Experimental
20 mm 40 mm 60 mm 20 mm 40 mm 60 mm
1.
2.
3.
4.
5.
6.
/3 Cortilone
450 pg/hr
/3 Cortilone
450 p.g/hr
I3Cortol
460 pg/hr
Hydrocortisone
750 jig/hr
Dexamethasone
37.5 jig/hr
Methylprednisolone
1.5 mg/hr
0.70
0.64
0.12
0.33
0.19
0.48
0.76
0.66
0.15
0.36
0.23
0.67
0.16
0.44
0.33
0.15
2.55
0.33
0.49
0.57
0.59
0.08
3.29
0.84
0.57
0.67
0.56
0.08
3.20
1.15
0,75
0.72
0.64
0.13
4.00
1.37
0.44
0.21
0.27
0.10
0.95
0.79
1.04
0.78
0.70
0.61
0.78
0.66
1.64
1.20
1.12
0.69
0.93
1.24
1.87
1.50
1.10
0.81
0.92
1.28
1.86
1.52
1.15
1.04
1.04
1.53
0.75
0.63
0.42
0.24
0.18
0.69
See 1egend of Table 1.
from the luminal surface of the tubular epithelial cell [12, 14,
22]. The rapid onset of action in all systems studied, whether in
vitro or in vivo, suggests that the substance is a hormone rather
than a pre- or a pro-hormone and lends further support to a
non-genomic effect [21].
The present studies demonstrate a clear relationship between
the dose of NH administered and the magnitude of natriuresis
observed. NH is active both orally and intravenously. NH is
naturally occurring. Finally, it produces limited kaliuresis.
These facts suggest that it could have an important therapeutic
role in sodium and water retaining states. They also differenti-
ate it from ANF and BNP, which are not active by mouth, from
digitalis-like substances which produce kaliuresis without na-
triuresis; and from the other steroids presented in Table 8. A
detailed treatment of the effects of steroids on sodium handling
by the kidney is contained in two recent symposia [23—28).
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